From the Department of Anesthesiology, Zucker School of Medicine at Hofstra Northwell, Hempstead, New York.
Cardiac Surgery Research and Perfusion, Flinders University and Flinders Medical Center, Adelaide, South Australia, Australia.
Anesth Analg. 2018 Feb;126(2):413-424. doi: 10.1213/ANE.0000000000002613.
Despite more than a half century of "safe" cardiopulmonary bypass (CPB), the evidence base surrounding the conduct of anticoagulation therapy for CPB has not been organized into a succinct guideline. For this and other reasons, there is enormous practice variability relating to the use and dosing of heparin, monitoring heparin anticoagulation, reversal of anticoagulation, and the use of alternative anticoagulants. To address this and other gaps, The Society of Thoracic Surgeons, the Society of Cardiovascular Anesthesiologists, and the American Society of Extracorporeal Technology developed an Evidence Based Workgroup. This was a group of interdisciplinary professionals gathered to summarize the evidence and create practice recommendations for various aspects of CPB. To date, anticoagulation practices in CPB have not been standardized in accordance with the evidence base. This clinical practice guideline was written with the intent to fill the evidence gap and to establish best practices in anticoagulation therapy for CPB using the available evidence. To identify relevant evidence, a systematic review was outlined and literature searches were conducted in PubMed using standardized medical subject heading (MeSH) terms from the National Library of Medicine list of search terms. Search dates were inclusive of January 2000 to December 2015. The search yielded 833 abstracts, which were reviewed by two independent reviewers. Once accepted into the full manuscript review stage, two members of the writing group evaluated each of 286 full papers for inclusion eligibility into the guideline document. Ninety-six manuscripts were included in the final review. In addition, 17 manuscripts published before 2000 were included to provide method, context, or additional supporting evidence for the recommendations as these papers were considered sentinel publications. Members of the writing group wrote and developed recommendations based on review of the articles obtained and achieved more than two thirds agreement on each recommendation. The quality of information for a given recommendation allowed assessment of the level of evidence as recommended by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Recommendations were written in the three following areas: (1) heparin dosing and monitoring for initiation and maintenance of CPB; (2) heparin contraindications and heparin alternatives; and (3) reversal of anticoagulation during cardiac operations. It is hoped that this guideline will serve as a resource and will stimulate investigators to conduct more research and to expand on the evidence base on the topic of anticoagulation therapy for CPB.
尽管体外循环(CPB)已有超过半个世纪的“安全”应用,但围绕 CPB 抗凝治疗的证据基础尚未被组织成简明的指南。由于这个原因和其他原因,肝素的使用和剂量、肝素抗凝监测、抗凝逆转以及替代抗凝剂的使用等方面存在巨大的实践差异。为了解决这个问题和其他差距,胸外科医师学会、心血管麻醉医师学会和美国体外循环技术学会成立了一个循证工作组。这是一个跨学科专业人员组成的小组,旨在总结证据并为 CPB 的各个方面制定实践建议。迄今为止,CPB 的抗凝实践尚未根据证据基础进行标准化。本临床实践指南的编写目的是填补证据空白,并利用现有证据在 CPB 抗凝治疗中建立最佳实践。为了确定相关证据,制定了系统评价,并使用美国国立医学图书馆搜索词列表中的标准化医学主题词(MeSH)术语在 PubMed 中进行了文献搜索。搜索日期包括 2000 年 1 月至 2015 年 12 月。搜索产生了 833 个摘要,由两名独立审查员进行了审查。一旦进入全文审查阶段,写作小组成员中的两名成员将评估纳入指南文件的 286 篇全文论文的纳入资格。96 篇手稿被纳入最终审查。此外,还包括了 17 篇发表于 2000 年前的论文,以提供建议的方法、背景或额外的支持证据,因为这些论文被认为是具有重要意义的文献。写作小组成员根据获得的文章撰写并制定了建议,并对每条建议达成了三分之二以上的一致意见。每条建议的信息质量允许根据美国心脏病学院基金会/美国心脏协会实践指南工作组的建议对证据水平进行评估。建议在以下三个领域中撰写:(1)CPB 启动和维持时肝素的剂量和监测;(2)肝素的禁忌证和肝素替代品;(3)心脏手术期间抗凝的逆转。希望本指南将成为一个资源,并激发研究人员进行更多的研究,并在 CPB 抗凝治疗的主题上扩展证据基础。